OKV-119

OKV-119 is a miniature, subdermal drug implant designed for the long-term delivery of exenatide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), primarily developed for the treatment of obesity and diabetes in companion animals such as cats and dogs. The device leverages Vivani Medical’s proprietary NanoPortal technology to provide smooth, steady release of exenatide over extended periods—currently demonstrated up to 84 days in cats, with future studies aiming for six months or longer. Exenatide mimics the effects of endogenous GLP-1 by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and enhancing satiety signals. These actions contribute to improved glycemic control and weight loss. The implant is inserted subdermally during routine veterinary visits and is intended to improve medication adherence by reducing dosing frequency. Developed through a partnership between Okava Pharmaceuticals (focused on veterinary applications) and Vivani Medical (technology provider), OKV-119 represents an innovative approach to managing chronic metabolic diseases in pets[2][3][4][5][6].

Brand names

OKV-119OKV119OKV 119

Other names

OKV-119 exenatide implantOKV119 exenatide implantOKV 119 exenatide implant